Responsibilities

1. Familiar with the drug development cycle, serving as the clinical trial leader in the clinical project development and operation team, and collaborating across departments throughout the entire cycle to execute the company's clinical trials.

2. As a member of the core clinical trial team, I can independently solve problems that arise during the execution of the responsible clinical trial and seek guidance on more complex issues as needed.

3. Plan, track, and manage designated clinical trial budgets to ensure compliance with budget plans.

4. Complete other tasks assigned by the line manager.

Qualifications

1. A degree in Medicine, Clinical Science, or a related field, with a full-time Master’s degree or higher (MD and/or Ph.D. preferred) from a 985/211 university.
2. Deep understanding of oncology or autoimmune fields; preferred candidates will have over 3 years of clinical research project experience in oncology or autoimmune fields at a multinational corporation (MNC), with CAR-T clinical trial experience being a plus.
3. Excellent communication skills in both Chinese and English.
4. Outstanding communication, coordination, and cross-departmental collaboration abilities.
5. Strong sense of responsibility and professionalism; demonstrates excellent leadership and decision-making skills in cross-functional project team environments.
6. Good awareness of the commercial and regulatory strategies in drug development, with the ability to build effective relationships with external experts.
7. Values innovation and is open to challenges.

About GRACELL

As a member of the AstraZeneca Group, Gracell is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich pipeline of autologous and allogeneic product candidates designed to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality and a lack of effective CAR-T therapies for solid tumors and autoimmune diseases.